Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-8 at European Group for Blood and Marrow Transplantation centres. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B, et al. European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation in multiple myeloma. Gahrton G, Tura S, Ljungman P, Belanger C, Brandt L, Cavo M, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. 1996 348:346.īarlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, et al. 2004 103:4362–4.Īschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Lokhorst HM, Schattenberg A, Cornelissen JJ, van Oers MH, Fibbe W, Russell I, et al. Graft-versus-myeloma effect: proof of principle. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. This supports the existence of durable GVM effect enhancing myeloma control with subsequent therapies. Median post relapse survival was 41.5 months in auto-auto and 62.3 months in auto-allo (HR = 0.71, P < 0.001). 19.7%, P < 0.001), while risk of disease progression was higher in auto-auto (10 year 77.2% vs. Risk of non-relapse mortality was higher in auto-allo (10 year 8.3% vs. Progression-free survival was also improved in auto-allo (HR = 0.84, P = 0.004). 44.1% at 10 years ( P = 0.01) for auto-auto and auto-allo, respectively. Median overall survival (OS) was 78.0 months in auto-auto and 98.3 months in auto-allo (HR = 0.84, P = 0.02). Median follow up of survivors was 118.5 months. There were 899 patients in auto-auto and 439 in auto-allo. We obtained individual patient data from participants of four trials comparing auto-auto vs. A pooled analysis of multiple trials with extended follow up provides an opportunity to compare these strategies. Trials comparing these two strategies relied on availability of HLA-matched sibling donors for arm allocation (biological randomization) and yielded conflicting results. Contrary to tandem autologous transplant (auto-auto), autologous followed by reduced intensity conditioning allogenic transplantation (auto-allo) offers graft-versus-myeloma (GVM) effect but with higher toxicity.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |